Symbio Pharmaceuticals Limited (4582) AI Stock Analysis

1 Followers

Symbio Pharmaceuticals Limited

(TSE/TYO:4582)

Select Model

Rating:39Underperform

Price Target:JPY 49.00▼(-16.95% Downside)

Action:reiterated

Date:11/06/26

The stock receives a very low score primarily driven by critical fundamental weaknesses, including an existential financial crisis, aggressive cash burn, and negative margins. Heavily oversold technicals and poor valuation metrics further underscore the high risk and lack of profitability.

Positive Factors

High Gross MarginA strong gross margin indicates that the underlying products can retain meaningful value after direct costs. If the company can control selling, research, and other operating expenses, this gross-profit base could support improved operating leverage and a more sustainable path toward profitability.

Negative Factors

Persistent Revenue DeclineSeveral consecutive years of falling revenue indicate weakening commercial scale rather than a single-quarter fluctuation. Continued contraction can reduce operating leverage, limit funding available for development, and make it harder for the company to absorb fixed research, regulatory, and commercial costs.

Symbio Pharmaceuticals Limited (4582) vs. iShares MSCI Japan ETF (EWJ)

Market Cap: JPY 3.03B
Dividend Yield: ―
Average Volume (3M): 3.30M
Price to Earnings (P/E): -0.6
Beta (1Y): -0.10
Revenue Growth: -30.58%
EPS Growth: 6.93%
Country: Japan
Employees: 91
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Pharmaceuticals

Symbio Pharmaceuticals Limited Business Overview & Revenue Model

Company Description

SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally. It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers...

Symbio Pharmaceuticals Limited Financial Statement Overview

Summary

The company faces severe financial distress with a collapse in revenue, deeply negative profit margins, and rapid erosion of equity. High cash burn and new debt highlight critical liquidity and solvency risks.

Income Statement

8Very Negative

Balance Sheet

22Negative

Cash Flow

5Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.06B	1.31B	2.45B	5.59B	10.01B	8.25B
Gross Profit	778.13M	947.34M	1.87B	4.41B	7.60B	5.80B
EBITDA	-6.05B	-4.60B	-3.78B	-714.00M	2.06B	1.11B
Net Income	-6.09B	-4.78B	-3.83B	-1.96B	1.18B	2.03B
Balance Sheet
Total Assets	932.36M	3.87B	4.97B	8.17B	17.43B	15.18B
Cash, Cash Equivalents and Short-Term Investments	253.99M	2.88B	3.96B	6.52B	6.28B	3.86B
Total Debt	800.00M	1.98B	0	0	0	0
Total Liabilities	2.23B	2.60B	770.77M	8.14B	8.92B	8.43B
Stockholders Equity	-1.30B	1.27B	4.20B	7.21B	8.51B	6.75B
Cash Flow
Free Cash Flow	0	-4.58B	-3.44B	-427.48M	1.57B	76.20M
Operating Cash Flow	0	-4.58B	-3.42B	-194.69M	1.61B	140.04M
Investing Cash Flow	0	-75.92M	-3.96M	-376.70M	-47.13M	-70.85M
Financing Cash Flow	0	3.62B	708.47M	680.16M	627.99M	-71.92M

Symbio Pharmaceuticals Limited Technical Analysis

Technical Analysis SentimentPositive

Last Price59.00

Price Trends

50DMA54.78Positive

100DMA61.93Negative

200DMA80.83Negative

Market Momentum

MACD0.83Negative

RSI55.44Neutral

STOCH25.00Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4582, the sentiment is Positive. The current price of 59.00 is above the 20-day moving average (MA) of 51.60, above the 50-day MA of 54.78, and below the 200-day MA of 80.83, indicating a neutral trend. The MACD of 0.83 indicates Negative momentum. The RSI at 55.44 is Neutral, neither overbought nor oversold. The STOCH value of 25.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4582.

Symbio Pharmaceuticals Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

JP:4582 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
JP:4574	69Neutral	JPY 13.27B	19.21	―	1.25%	13.30%	66.38%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
JP:4539	47Neutral	JPY 5.52B	-11.50	―	3.30%	0.31%	-194.72%
JP:4512	45Neutral	JPY 10.00B	55.30	―	1.22%	23.41%	149.71%
JP:4582	39Underperform	JPY 5.25B	-0.65	―	―	-30.58%	6.93%
JP:4597	38Underperform	JPY 6.55B	-8.22	-53.67%	―	109.82%	61.98%
JP:4586	37Underperform	JPY 2.77B	-2.67	―	―	167.44%	49.38%

* Healthcare Sector Average

Performance Comparison

JP:4582 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
JP:4582	Symbio Pharmaceuticals Limited	59.00	-47.00	-44.34%
JP:4597	Solasia Pharma KK	25.00	-8.00	-24.24%
JP:4512	Wakamoto Pharmaceutical Co., Ltd.	287.00	7.36	2.63%
JP:4539	Nippon Chemiphar Co., Ltd.	1515.00	34.18	2.31%
JP:4574	Taiko Pharmaceutical Co., Ltd.	263.00	-27.00	-9.31%
JP:4586	Medrx Co., Ltd.	38.00	-90.00	-70.31%

Symbio Pharmaceuticals Limited Corporate Events

SymBio Pharmaceuticals Swings to Deep Negative Equity as Losses Mount in 2026

Oct 29, 2026

SymBio Pharmaceuticals reported a sharp deterioration in its financial position for the first nine months of 2026, with net sales dropping 25.6% year-on-year to ¥722 million and losses deepening as operating profit fell to a ¥4,870 million deficit. T...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 05, 2026

Symbio Pharmaceuticals Limited AI Stock Analysis